Delota Reports Financial Results for the Year Ended March 31, 2026
Highlights: Total revenue of $34.8 million for the Year Ended 2026Total System-Wide Revenue of $39.8 million for the Year Ended...
Month: July 2026
Dario Launches Integrated GLP-1 Program, Combining Its Digital Chronic Care Platform with Provider-Backed Clinical Care in a Single End-to-End Experience
First commercial offering from Dario's collaboration with Beluga Health adds licensed provider evaluation, prescribing and ongoing clinical oversight directly inside...
Akido Announces the First AI-Native Health System in the US
Akido's ScopeAI-powered network gives 1 million patients access to careLOS ANGELES, July 30, 2026 /PRNewswire/ -- Akido today announced it is...
CentralReach Continues to Scale as Category Leader in Autism and IDD Care Software, Names Chief Sales Officer Dan Freund
Company Continues to Grow Revenue More Than 20% and Serves Over 4,600 CustomersFORT LAUDERDALE, Fla., July 30, 2026 /PRNewswire/ --...
Infinitus Launches AI-First, Human-Backed Hub Solution to Replace Specialty Pharma’s Legacy Call-Center Infrastructure
AI absorbs routine volume and human experts own every judgment call – cutting administrative cost up to 30% while ensuring...
Tenon Medical, Inc. Sets Date for Second Quarter 2026 Earnings
LOS GATOS, CA / ACCESS Newswire / July 30, 2026 / Tenon Medical, Inc. (NASDAQ:TNON)("Tenon" or the "Company"), a medical...
Saudi Arabia Ranks No. 1 Among Next-Wave EHR Markets as National Buying Cycle Accelerates
Black Book study of 128 Saudi health IT leaders finds interoperability, cybersecurity, regulatory agility and in-country delivery are reshaping procurement....
TempraMed Uplists to OTCQB Venture Market and Achieves DTC Eligibility, Expanding Access to U.S. Investors
Toronto, Ontario--(Newsfile Corp. - July 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company") is pleased...
JASCO and Bioz Celebrate a Longstanding Partnership Advancing Scientific Product Discovery
PALO ALTO, CA / ACCESS Newswire / July 30, 2026 / Bioz, Inc., the leading scientific marketing platform that helps...
Relation unveils MORGAN, the next-generation model of cellular biology
LONDON, July 30, 2026 (GLOBE NEWSWIRE) -- Relation today announced MORGAN (Multi-Omic Regulatory Genomics using Artificial Neural Networks), our flagship...
Actimed Therapeutics Strengthens Board with Appointment of Dr. Anders Ullman
Dr. Anders Ullman Actimed Therapeutics Strengthens Board with Appointment of Dr. Anders Ullman London, UK – 30 July 2026. Actimed Therapeutics...
Relation Announces Expanded Collaboration with GSK
Up to $110 million upfront and success-based milestones collaboration will generate large-scale human cellular perturbation datasets to advance understanding of...
AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa
AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa Nippon Shinyaku exercises its...
Curium advances plans for second investment in Romania to expand access to advanced nuclear medicine
Proposed expansion in the Cluj-Napoca region intended to strengthen PET imaging supply and support continued development of regional nuclear medicine...
Sugar Reset Drops Label Guide: What the Supplement Facts Panel, Serving Directions, and Safety Statements Disclose for 2026
Sugar Reset Drops' Chromium Dose, Grapefruit and Licorice Interaction Details, and 20% Refund Fee ExplainedLargo, FL, July 30, 2026 (GLOBE...
Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded
Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded July 30, 2026 Q2 sales growth of...
Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance
H1 2026 results with sales growth of 23.5% at CER1, or 20.4% as reported, with the portfolio beyond Somatuline® achieving...
Regulated information: Fagron delivers strong H1 2026 performance with 16% topline growth and reiterates FY 2026 guidance
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 30 July 2026 – 7:00 AM CET Fagron delivers strong H1 2026 performance with...
QUVIVIQ sales increased 62% year-on-year as Idorsia advances key drivers of future growth
Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ™ (daridorexant) sales reached CHF 91 million in H1 2026, up 62%...
Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use
For investor audiences and media only Second quarter 2026 total revenues decreased by 3% to US$90.2 million, compared to the...